Sumitomo Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SUMITOMO PHARMA
SUMITOMO PHARMA has six approved drugs.
There are forty-eight US patents protecting SUMITOMO PHARMA drugs.
There are six hundred and seventy patent family members on SUMITOMO PHARMA drugs in fifty-seven countries and fifty-four supplementary protection certificates in sixteen countries.
Summary for Sumitomo Pharma
| International Patents: | 670 |
| US Patents: | 48 |
| Tradenames: | 6 |
| Ingredients: | 6 |
| NDAs: | 6 |
Drugs and US Patents for Sumitomo Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sumitomo Pharma Am | GEMTESA | vibegron | TABLET;ORAL | 213006-001 | Dec 23, 2020 | RX | Yes | Yes | 12,180,219 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Sumitomo Pharma Am | LONHALA MAGNAIR KIT | glycopyrrolate | SOLUTION;INHALATION | 208437-001 | Dec 5, 2017 | DISCN | Yes | No | 10,744,277 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-001 | May 21, 2020 | DISCN | Yes | No | 10,821,074 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sumitomo Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-005 | May 21, 2020 | 8,663,687 | ⤷ Start Trial |
| Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-001 | Nov 8, 2013 | 11,364,247 | ⤷ Start Trial |
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-001 | May 21, 2020 | 8,603,514 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Sumitomo Pharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2004067535 | ⤷ Start Trial |
| Russian Federation | 2476197 | ⤷ Start Trial |
| Honduras | 2010002030 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sumitomo Pharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1453521 | 39/2015 | Austria | ⤷ Start Trial | PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211 |
| 1453521 | C201630040 | Spain | ⤷ Start Trial | PRODUCT NAME: ETINILESTRADIOL Y MEZCLA DE LEVONORGESTREL Y ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: 80340; DATE OF AUTHORISATION: 20160122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150211 |
| 1591446 | PA2021529 | Lithuania | ⤷ Start Trial | PRODUCT NAME: RELUGOLIKSAS ARBA JO DRUSKA ; REGISTRATION NO/DATE: EU/1/21/1565 20210716 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
